ImStem Biotechnology, Inc. is an innovative biopharmaceutical company targeting areas in autoimmune, degenerative, and rare orphan diseases. With our state-of-the-art technology, we aspire to improve patient treatment outcomes and quality of health, as well as advance the knowledge of regenerative medicine globally. Our proprietary T-MSC technology (trophoblast-derived mesenchymal stem cells) has opened up a new chapter in the field of pluripotent stem cell therapy. Through our proprietary differentiation method, we derive mesenchymal stem cells (MSCs) from human embryonic stem cells (hESCs) via a trophoblast-like intermediate stage. In 2020, T-MSC cell therapy was accepted by the FDA to proceed to clinical trial in multiple sclerosis patients, which we believe became the first hESC based allogenic stem cell therapy to be administered intravenously for this potential indication. Furthermore, our T-MSC technology has been granted 11 patents worldwide. In Q3 2021, ImStem has initiated Phase I Clinical Trial in the United States.

Contact ImStem Biotechnology, Inc.
Visit Website